Molecular Cancer Genetics & Translational Research Lab, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh - 202002, India.
Epigenomics. 2023 Apr;15(8):517-537. doi: 10.2217/epi-2023-0142. Epub 2023 Jun 14.
Epigenetic changes play a significant role in cancer progression, maintenance and therapy resistance. Generally, epigenetic modifications are reversible, thereby gaining attention for therapeutic interventions. However, limited efficacy and therapy resistance remain the significant limitations of conventional and epigenetic anticancer therapies. Recently, combination therapies with epigenetic drugs (epi-drugs) and conventional anticancer treatment have gained widespread attention. Here, epi-drugs are administered with anticancer therapies to increase their therapeutic efficacy and sensitize cancer cells resistant to therapies. This review summarizes the mechanism of epi-drugs in reversing resistance to anticancer therapies. Further, the challenges faced during developing combination therapies with epi-drugs are discussed. We believe the clinical benefit of combination therapies could be increased by overcoming the challenges faced during epi-drug development.
表观遗传改变在癌症的进展、维持和治疗耐药中起重要作用。一般来说，表观遗传修饰是可逆的，因此作为治疗干预措施引起了关注。然而，疗效有限和治疗耐药仍然是传统和表观遗传学抗癌治疗的重大限制。最近，联合应用表观遗传药物（epi-drugs）和传统抗癌治疗已受到广泛关注。在这里，epi-drugs 与抗癌治疗联合应用以提高其治疗效果并使对治疗耐药的癌细胞敏感。这篇综述总结了 epi-drugs 逆转抗癌治疗耐药的机制。此外，还讨论了联合应用 epi-drugs 时面临的挑战。我们相信，通过克服 epi-drug 开发过程中面临的挑战，可以增加联合治疗的临床获益。
